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Background: Patients on hemodialysis are at high risk for hepatitis C virus (HCV) infection if measures for effective
control of HCV infection in the hemodialysis environment are not implemented. Whereas in developed countries
isolated small-scale outbreaks of HCV in hemodialysis units are occasionally reported, HCV transmission in the
hemodialysis environment still represents a substantial problem in low-resource countries. This study systematically
assessed the prevalence of HCV infection among all patients at all hemodialysis centers in Kosovo, determined the
HCV genotype distribution, and reviewed the main risk factors associated with HCV infection in this group of
patients.
Methods: From January to March 2013, blood samples from all patients undergoing hemodialysis at all seven
hemodialysis centers in Kosovo were collected. The samples were screened for the presence of anti-HCV antibodies,
and seropositive samples were also tested for HCV RNA. Genotyping was performed by sequencing the core region
of the HCV genome. Subsequently, face-to-face interviews were conducted with consented patients attending
hemodialysis in December 2015 and with the management of all hemodialysis centers in Kosovo.
Results: The overall seroprevalence of HCV infection among hemodialysis patients in Kosovo was 53.0% (354/668),
ranging from 22.3 to 91.1% at different centers. HCV RNA was detected in 323/354 (91.2%) seropositive patients. The
most frequent HCV genotype was genotype 1a (62.2%), followed by genotypes 4d (33.1%), 1b (4.0%), and 2c (0.7%).
The duration of hemodialysis and receiving dialysis at more than one center were identified as independent significant
predictors of anti-HCV positivity. Shortage of staff, lack of resources, and inconsistent use of hygienic precautions and/
or isolation strategies were observed.
Conclusions: The prevalence of HCV infection among hemodialysis patients in Kosovo is extremely high. The relatively
low prevalence of HCV infection in the general population, predominance of two otherwise rare HCV genotypes
among hemodialysis patients, and longer history of hemodialysis as a predictor of HCV infection all indicate
nosocomial transmission due to inappropriate infection control practices as the main transmission route.
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Hepatitis C virus (HCV) is one of the leading causes
of acute and chronic hepatitis, cirrhosis of the liver,
hepatocellular carcinoma, and related death [1, 2].
Up to 1% of the world’s population is estimated to
be infected with HCV, corresponding to more than
71 million people with a viremic infection [3]. The
prevalence of HCV-specific antibodies in the general
population varies from less than 1.5% in North
America and some parts of South America to over
3.5% in some regions of Africa and Asia [3]. In de-
veloped countries, most of the incident hepatitis C
cases are due to acquisition and transmission among
people that inject drugs, whereas in developing
countries healthcare-associated transmission due to a
poor standard of infection control and prevention
remains the main route for HCV transmission [4, 5].
The largest documented iatrogenic HCV transmis-
sion occurred in Egypt due to mass population-based
antischistosomal treatment involving administration
of tartar emetic injections from 1960s to 1980s [6].
Patients on hemodialysis are at higher risk for HCV
infection if measures for effective control of HCV
infection in the hemodialysis environment are not
implemented. Whereas in developed countries isolated
small-scale HCV outbreaks in hemodialysis units are re-
ported only occasionally, HCV transmission in the
hemodialysis environment still represents a substantial
problem in low-resource countries [7–9].
Kosovo is a small lower-middle-income country
with 1.7 million inhabitants in southeastern Europe
that has recently gone through war and postwar dif-
ficulties. Data on prevalence of HCV infection in
Kosovo, and particularly among hemodialysis pa-
tients, are scarce. The seroprevalence of HCV infec-
tion was first assessed among Kosovar blood donors
between 2000 and 2003 and was found to be 0.3%
(206/70,348) [10]. The anti-HCV prevalence in the
general population was studied in a single region in
Kosovo in 2005 and reported to be 0.5% (7/1287),
whereas the seroprevalence in hemodialysis patients
from the same region in the same period was 86.4%
(57/66) [11, 12]. In 2008 all patients treated at
hemodialysis centers were tested and 42.9% (250/
583) were found to be anti-HCV positive [13].
This study systematically assessed the prevalence
of HCV infection among all patients at all
hemodialysis centers in Kosovo, determined the
HCV genotype distribution, and reviewed factors as-
sociated with HCV transmission for the first time in
order to obtain baseline data before implementing
the infection control measures and treatment strat-
egies necessary to prevent the further spread of
HCV infection in this specific healthcare setting.Materials and methods
All 668 patients that were treated with hemodialysis
between January and March 2013 at all seven
hemodialysis centers in Kosovo were included in this
study. Blood samples were obtained by venipuncture
at dialysis centers and were first screened for the
presence of antibodies against HCV, using the ELISA
anti-HCV test (Axiom, Bürstadt, Germany), following
the manufacturer’s instructions. All samples that
tested anti-HCV positive were also tested for HCV
RNA using the COBAS AmpliPrep/COBAS TaqMan
HCV Qualitative Test, v2.0 (Roche Molecular Diag-
nostics, Meylan, France).
HCV genotyping was performed in all viremic
samples by sequencing the core region of the HCV
genome, as previously described [14]. Briefly, viral
nucleic acid was extracted from 200 μl of patient’s
plasma samples, using the MagnaPure Compact Nu-
cleic Acid Isolation kit I on the MagNA Pure Com-
pact instrument (Roche Diagnostics, Mannheim,
Germany) and amplified using SuperScriptTM III
One-Step RT-PCR System with Platinum® Taq High
Fidelity (Invitrogen, Carlsbad, CA, USA) and primers
Sc2/Ac2 [14]. If no polymerase chain reaction (PCR)
product was obtained, nested PCR with S7/A5
primers and the FastStart High Fidelity PCR System
(Roche Diagnostics) was employed [14]. The ac-
quired 441 bp or 355 bp amplicons of the HCV core
region were purified with the addition of enzymes
Exonuclease I and FastAP (Thermo Fisher Scientific,
Waltham, MA, USA) and sequenced using a BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems, Foster City, CA, USA) with the nested S7
primer. A BigDyeXTerminator Purification Kit (Applied
Biosystems) was used for the removal of unincorporated
dye terminators from the sequencing reactions. Sequen-
cing was performed on the 3500 Genetic Analyzer (Ap-
plied Biosystems), and the HCV genotype determined
using the NCBI genotyping tool [15], with the addition of
genotype reference set 2012, retrieved from HCV Se-
quence Alignments [16].
In addition, all patients receiving hemodialysis at seven
centers in Kosovo in December 2015 were invited to
participate in the study and face-to-face interviews were
conducted with those patients who signed written in-
formed consent. The following information was col-
lected: age, sex, education, employment status, duration
of hemodialysis, location of hemodialysis, blood transfu-
sion, surgical and dental interventions, and other risk
factors (see Additional file 1: Table S1). Anti-HCV test
results for the patients of the 2015 cohort were obtained
from their medical records. Interviews were conducted
with the management of hemodialysis centers with an
emphasis on infection control and issues related to
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staffing) (see Additional file 2: Table S2).
The statistical analysis was conducted using SPSS soft-
ware, version 17.0. Data were expressed as mean ± stand-
ard deviation (SD), median and inter-quartile range, or
frequencies, as appropriate. Differences between sub-
groups were assessed using a χ2 (chi-squared) test, Fish-
er’s exact test, Student’s t-test, and an analysis of
variance test. The backward Poisson regression was used
to assess the independent effect of a variable, and the
prevalence ratios and their respective robust 95% confi-
dence intervals were calculated. The Wald test was used
as a statistical test. A p-value of less than 0.05 was con-
sidered statistically significant.Results
As shown in Table 1, the overall seroprevalence of HCV
infection among 668 hemodialysis patients in Kosovo
was 53.0% (354/668). The highest seroprevalence was
observed at Center 7 (91.1%) (Table 1).
HCV RNA was detected in 323/354 (91.2%) seroposi-
tive hemodialysis patients. Out of 323 viremic patients,
275 (85.1%) were successfully genotyped.
Nationwide, the most frequent HCV genotype among
hemodialysis patients was genotype 1a (62.2%) followed by
genotypes 4d (33.1%), 1b (4.0%), and 2c (0.7%) (Table 1).
No other HCV genotypes were identified.
The distribution of HCV genotypes differed signifi-
cantly among centers (Table 1). Subtype 1a was the most
prevalent at all but one center, ranging from 24.4% at
Center 3 to 100% at Center 5. The HCV genotype 4d
was the most prevalent (73.2%) at Center 3 and was the
second most prevalent HCV genotype at the remaining
centers except Center 6, where it was the third most
prevalent after genotypes 1a and 1b. HCV genotype 1b
was detected in a total of only 11 patients. It was found
at all centers except Center 5. HCV genotype 2c was
found in two hemodialysis patients only, one each at
Center 4 and Center 6 (Table 1).Table 1 HCV seropositivity, HCV RNA positivity, and distribution of H
Hemodialysis
center






Center 1 188 42 (22.3) 39 (92.9)
Center 2 68 46 (67.6) 42 (91.3)
Center 3 75 51 (68.0) 45 (88.2)
Center 4 163 112 (68.7) 102 (91.1)
Center 5 39 13 (33.3) 9 (69.2)
Center 6 79 39 (49.4) 38 (97.4)
Center 7 56 51 (91.1) 48 (94.1)
Total 668 354 (53.0) 323 (91.2)Out of 708 patients receiving hemodialysis in Kosovo
in December 2015, 618 (87.3%) signed written informed
consent and were included in the survey. Of these 618
patients, 244 (39.5%) were anti-HCV positive. This co-
hort of patients differed from the initial HCV prevalence
study; namely, 477 (77.2%) of the patients also partici-
pated in 2013.
In the study population, 51.6% were males, with a mean
age of 56.3 (± 12.7 years; Table 2). The majority of patients
were married (83.2%), 54.5% were unemployed, and 34%
were retired. The level of education of the patients was as
follows: none (15.5%), primary education (39.6%), secondary
education (32.3%), and higher education (9.7%). Nine (1.5%)
dialysis patients were healthcare workers (data not shown).
Factors determined to be significantly associated with
the anti-HCV positivity in the unadjusted Poisson ana-
lysis were as follows: age (prevalence ratio (PR) = 0.985,
95% confidence interval (CI): 0.972–0.998, p = 0.021),
duration of hemodialysis (PR = 1.032, 95% CI: 1.020–
1.044, p < 0.0001), hemodialysis at more than one center
(PR = 1.251, 95% CI: 1.086–1.442, p = 0.002), and blood
transfusion (PR = 1.188, 95% CI: 1.006–1.404, p = 0.043;
Table 2). The multivariate analysis determined the dur-
ation of hemodialysis and hemodialysis at more than
one center as independent significant factors associated
with anti-HCV positivity (adjusted prevalence ratio
(APR) = 1.032, 95% CI: 1.017–1.042, p < 0.0001; APR =
1.180, 95% CI: 1.020–1.365, p = 0.026; Table 2).
The duration of hemodialysis was significantly associ-
ated with HCV infection. Eleven patients with terminal
chronic kidney insufficiency had started hemodialysis
over 20 years earlier, of whom 10 (90.9%) were found to
be anti-HCV positive in this study. In contrast, the ma-
jority of patients had started hemodialysis in the previ-
ous 9 years and had an anti-HCV positive rate of 31.5%
(Table 2).
Patients that had received blood transfusion in the past
had significantly higher anti-HCV prevalence (p = 0.043;
Table 2). In addition, the number of blood transfusions re-











15 (46.9) 3 (9.4) 0 14 (43.8) 32 (82.1)
25 (75.8) 1 (3.0) 0 7 (21.2) 33 (78.6)
10 (24.4) 1 (2.4) 0 30 (73.2) 41 (91.1)
55 (63.2) 1 (1.1) 1 (1.1) 30 (34.5) 87 (85.3)
5 (100) 0 0 0 5 (55.6)
26 (78.8) 4 (12.1) 1 (3.0) 2 (6.1) 33 (86.8)
35 (79.5) 1 (2.3) 0 8 (18.2) 44 (91.7)
171 (62.2) 11 (4.0) 2 (0.7) 91 (33.1) 275 (85.1)
Table 2 Association of variables with anti-HCV positivity among patients on hemodialysis in December 2015 in Kosovo, as
determined by univariate and multivariate logistic regression analysis
Explanatory variable n % Anti-HCV positive (%) Unadjusted PR CI 95% p-value Adjusted PR CI 95% p-value
Sex
Female 299 48.4 42.8 ref (1) 0.498 ref (1) 0.480




0.985 0.972–0.998 0.021* 0.997 0.992–1.003 0.327
Age (years)
≤ 39 52 8.4 51.9
40–49 96 15.5 41.7
50–59 178 28.8 40.4
60–69 180 29.1 38.9
≥ 70 112 18.1 31.3
Duration of dialysis (years)
Mean ± SD
8.8 ± 5.7
1.032 1.020–1.044 < 0.0001* 1.032 1.017–1.042 < 0.0001*
Duration of dialysis (years)
≥ 20 11 1.8 90.9
10–19 83 13.4 83.1
≤ 9 520 84.1 31.5
Missing 4 0.7
Hemodialysis at regional dialysis center
Center 1 167 27.0 18.0 ref (1) 0.060 ref (1) 0.065
Center 2 63 10.2 69.8 1.440 1.138–1.822 1.436 1.135–1.817
Center 3 78 12.6 33.3 1.130 0.891–1.433 1.134 0.894–1.439
Center 4 153 24.8 50.3 1.274 1.054–1.541 1.271 1.051–1.537
Center 5 45 7.3 35.6 1.149 0.862–1.531 1.163 0.871–1.552
Center 6 48 7.8 35.4 1.148 0.867–1.519 1.151 0.870–1.524
Center 7 64 10.4 53.1 1.298 1.019–1.654 1.302 1.022–1.659
Hemodialysis at more than one center
No 240 38.8 20.8 ref (1) 0.002* ref (1) 0.026*
Yes 378 61.2 51.3 1.251 1.086–1.442 1.180 1.020–1.365
Blood transfusion
No 142 23.0 21.8 ref (1) 0.043* ref (1) 0.341
Yes 476 77.0 44.7 1.188 1.006–1.404 0.92 0.817–1.041
SD standard deviation, PR unadjusted prevalence ratio, APR adjusted prevalence ratio; *p < 0.05; p (Wald test)
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blood transfusions received was 50 in the group of
anti-HCV positive patients, and 20 in the group of
anti-HCV negative patients (data not shown).
No statistically significant association of anti-HCV
positivity with other possible risk factors (transmission
among family members, surgical and dental interven-
tions, tattoos, injecting drugs, piercing, using others’
shaving kits, imprisonment, and hemophilia) were found
(data not shown).The second part of the survey was directed toward the
management of dialysis units and explored the reasons
for nosocomial transmission of HCV. At the time the
survey was carried out in 2015, a total of 18 medical
doctors specialized in nephrology, and 129 nurses were
employed at the hemodialysis centers in Kosovo, corre-
sponding to one medical doctor tending 39 patients and
one nurse tending five to six patients (Table 3).
Insufficient supply of gloves, sterile gauze, and disin-
fectants, as well as poor quality of gloves, were reported
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and staff were available for HCV-positive patients at all
centers; however, separate premises were dedicated for
isolation of HCV-positive patients at only five centers.
Anti-HCV test results were available prior to admission
for dialysis at two centers only (Table 3).
When questioned about possible reasons for high HCV
prevalence in their hemodialysis centers, the management
reported the following: human factors, surgical interven-
tions, blood transfusion, lack of appropriate isolation prem-
ises, postwar shortage of supplies, inability to screen
patients for HCV before dialysis is initiated, lack of HCV
testing capacities, and inadequate disinfection of machines.
Discussion
The results of this nationwide study showed a very high
prevalence of HCV infection among patients undergoing
hemodialysis at all centers in Kosovo in 2013. The over-
all HCV seroprevalence among hemodialysis patients in
Kosovo was 53.0%, ranging from 22.3 to 91.1% at differ-
ent centers. HCV seroprevalence exceeded 65.0% at four
out of seven centers.
A comparison of these results with those from 2008
[13], showed that the overall seroprevalence of HCV in-
fection in the hemodialysis setting in Kosovo significantly
increased from 42.9 to 53.0% in 5 years (χ2, p = 0.0004). In
contrast, a 2004 multicenter study showed that the preva-
lence of anti-HCV positive hemodialysis patients de-
creased markedly in one decade in the participating units
from most European countries [17]. The latest data on
HCV prevalence based on the cohort of patients surveyed
in December 2015 again displayed a lower anti-HCV
prevalence of 39.5%. The difference in the prevalence
could be due to enforced prevention following the results
of the 2013 study combined with the number of
anti-HCV positive patients that died or migrated to west-















Center 1 185 (26.1%) 37 5.8 56 Yes
Center 2 70 (9. 9%) 70 5.8 18 Yes
Center 3 94 (13.3%) 47 6.3 22 No
Center 4 176 (24.9%) 44 6.5 37 No
Center 5 50 (7.1%) 50 5 30 Yes
Center 6 64 (9.0%) 16 4.3 20 Yes
Center 7 69 (9.7%) 69 3.8 22 Yes
Total 708 39 5.5 205at the end of 2014 and the beginning of 2015 there was
large-scale emigration of the Kosovo population, which
could have affected this analysis [18].
The prevalence of HCV infection in hemodialysis pa-
tients in different countries in the region ranges from
12.7% in Serbia, 24.0% in Greece, 24.2% in Albania, and
32.0% in Macedonia to 58.9% in Bosnia and Herzegovina
[19–23]. However, in contrast to our study, all the re-
gional studies mentioned above assessed anti-HCV
prevalence among hemodialysis patients originating
from a single center, or a single region of a particular
country, and so selection bias should be taken in ac-
count when interpreting and comparing data.
In contrast to hemodialysis patients, HCV seroprevalence
in the general Kosovar population [11] and blood donors in
Kosovo is relatively low [10], indicating that the high preva-
lence of HCV infection among hemodialysis patients is not
a result of a high baseline prevalence of HCV infection in
patients entering hemodialysis centers. Out of 73,295 blood
donations reported between 2011 and 2013 in Kosovo, only
29 (0.04%) were identified as anti-HCV positive (data not
published). Interestingly, the 2015 survey identified blood
transfusion as a significant factor associated with HCV posi-
tivity in unadjusted statistical analysis. However, it is more
likely that HCV was transmitted due to inappropriate infec-
tion control practices during the blood transfusion proced-
ure at dialysis centers and not necessarily with
contaminated blood products because all blood donors in
Kosovo have been mandatorily screened for the presence of
anti-HCV since 1992. Unfortunately, HCV RNA or HCV
core antigen testing are still not part of the routine screening
of donors in Kosovo, and so some HCV-positive individuals
may have been missed. The use of blood transfusion among
hemodialysis patients has declined significantly since the
availability of erythropoietin in 2004 in Kosovo. In 2008,
erythropoietin was available to all dialysis patients, and so in
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an extent.
Nosocomial transmission of HCV among hemodialysis
patients from Kosovo is further supported by the results
of the 2015 survey, which identified the duration of
hemodialysis and receiving dialysis at more than one
center in Kosovo as independent factors significantly as-
sociated with anti-HCV positivity, and by the HCV
genotype distribution determined in the 2013 study.
Genotype 1a (62.2%) was the most frequent among
hemodialysis patients in Kosovo, followed by genotypes
4d (33.1%), 1b (4.0%), and 2c (0.7%). HCV genotype 1a
was predominant at all but one center, where genotype
4d prevailed (Table 1). Unfortunately, HCV genotype
distribution in other groups of HCV-infected patients in
Kosovo has not been studied so far, which prevents us
from concluding that this genotype distribution pattern
is specific to hemodialysis patients. However, according
to data available in the literature, neither genotype 1a or
4d are predominant either in hemodialysis patients or in
the HCV-infected population in general in any country
in the region, except Kosovo [24]. In a study performed
on 97 patients in neighboring Montenegro, both geno-
types 1a and 4d were identified as the third most preva-
lent genotypes in HCV-infected patients with 19.6%
share each [25], whereas in neighboring Macedonia
HCV genotype 4 has not been identified among 1167 pa-
tients studied [26]. In contrast to Kosovo, where HCV
genotype 1b was found in only 4.0% of hemodialysis pa-
tients and genotype 3 was not detected in a single
hemodialysis patient, these two genotypes predominate
among HCV-infected patients in general as well as
hemodialysis patients in all other countries in the region
[20, 25–31]. Further molecular epidemiology analysis of
HCV strains from our hemodialysis patients, which is cur-
rently in progress, might elucidate the routes of HCV trans-
mission at hemodialysis centers in Kosovo and irrevocably
confirm our hypothesis that the high prevalence of HCV
infection in hemodialysis patients in Kosovo is a result of
nosocomial transmission.
The management of hemodialysis centers reported a
number of issues that might have contributed to HCV
transmission at dialysis centers. Most centers reported a
shortage of staff, which directly relates to the quality of ser-
vices provided at hemodialysis centers [32]. At almost all
centers in Kosovo, the number of nephrologists and nurses
was lower than needed in comparison to the number of pa-
tients undergoing dialysis [33]. Nephrologists from four
centers did not work full-time at the hemodialysis units,
but worked part-time at other internal disease units of the
regional hospitals. In addition, none of the centers
employed an infection control nurse and renal dialysis tech-
nician. In addition, centers reported limited space available
to offer isolation for anti-HCV positive patients. However,even if isolation was possible, the problem remains that at
most centers in Kosovo new hemodialysis patients did not
have anti-HCV test results available prior to starting dialy-
sis, and HCV RNA or HCV core antigen testing are still
not performed in Kosovo today. The centers also struggled
with the availability of gloves, disinfectants, and sterile
gauze, and the overall absence of internal infection control
guidelines.
A limitation of this study is that at the time of the initial
HCV prevalence investigation in 2013 the demographic data
were not available and interviews were conducted on a mar-
ginally different cohort of patients receiving hemodialysis in
2015, which had a significantly lower HCV prevalence. An-
other major limitation is that only anti-HCV positive and
not anti-HCV negative patients were tested for the presence
of HCV RNA. Because some studies reported a substantial
proportion of HCV infected dialysis patients with undetect-
able anti-HCV antibodies in their serum, most likely due to
immune dysfunction [34], the prevalence of HCV infection
at hemodialysis centers in Kosovo might be underestimated.
Conclusions
In conclusion, a nationwide study of all hemodialysis cen-
ters in Kosovo showed an extremely high prevalence of
HCV infection in hemodialysis patients. The relatively low
prevalence of HCV infection in the general Kosovar popula-
tion, the significant increase in the anti-HCV prevalence
among hemodialysis patients in recent years, the predomin-
ance of two otherwise rare HCV genotypes in the region,
HCV infection associated with a longer duration of
hemodialysis, and hemodialysis at more than one center in-
dicate nosocomial transmission due to inappropriate infec-
tion control practices as the main HCV transmission route.
In most European countries, consistent reinforcement of
hygienic precautions and/or isolation strategies in
hemodialysis units has resulted in a substantial decrease of
both the incidence and prevalence of HCV infection in
hemodialysis units [35]. It seems that the WHO goal of
eliminating HCV by 2030 might be difficult to achieve in
settings similar to Kosovo if more rigorous measures are
not implemented for effective control of HCV infection in
the hemodialysis environment [36].Additional files
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